PACB

Pacific Biosciences of California, Inc.

Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.

Pacific Biosciences of California, Inc. (PACB) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Profitability (C-). The rating has held at C+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
A
Factor Score 4.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.9
EV / EBITDA -6.9
Rev Growth YoY 5.5%
Gross Margin 27.7%
Price Return 3M 62.0%
Price Return 12M 12.6%
Catalyst Signal 0.00
Market Cap $612.0M
TTM Revenue $161.4M
Price / Sales 3.8
ROE N/A

Historical Factor Score Progression

Held C+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C (2.3) C- (1.9) A (4.3) C+ (2.6) C+ (2.8)
2026-11-07 B- (3.0) C (2.3) D (1.4) A (4.3) C+ (2.7) C+ (2.7)
2026-10-31 B (3.2) C (2.2) D (1.5) A (4.3) C+ (2.7) C+ (2.8)
2026-10-24 B (3.2) C (2.2) D (1.5) B (3.2) C+ (2.6) C+ (2.5)
2026-10-17 B (3.2) C (2.2) D (1.5) C+ (2.7) C+ (2.6) C (2.5)
Page 1 of 8
…